US FDA approves Genzyme's stem cell transplant primer Mozobil
This article was originally published in Scrip
Executive Summary
The US FDA has approved Genzyme's stem cell transplantation primer Mozobil (plerixafor injection), for use in combination with granulocyte-colony stimulating factor (G-CSF) to mobilise haematopoietic stem cells from the bone marrow into the bloodstream for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma. The product was also granted orphan status.